分析医药研发生产力——需要新视角。
Analysis of pharma R&D productivity - a new perspective needed.
机构信息
Technische Hochschule Ingolstadt, THI Business School, Esplanade 10, DE-85049 Ingolstadt, Germany; University of St. Gallen, Institute of Technology Management, Dufourstrasse 40a, CH-9000 St. Gallen, Switzerland.
Novartis, Global Drug Development Patient Safety, Forum 1, CH-4002 Basel, Switzerland.
出版信息
Drug Discov Today. 2023 Oct;28(10):103726. doi: 10.1016/j.drudis.2023.103726. Epub 2023 Jul 26.
R&D productivity continues to be the industry's grand challenge. We analyzed the R&D input, output, and outcome of 16 leading research-based pharmaceutical companies over 20 years (2001-2020). Our analysis shows that pharma companies increased their R&D spending at a compound annual growth rate of 6% (2001-2020) to an average R&D expenditure per company of $6.7 billion (2020). The companies in our investigation launched 251 new drugs representing 46% of all CDER-related FDA approvals in the past 20 years. The average R&D efficiency of big pharma was $6.16 billion total R&D expenditures per new drug. Almost half of the leading companies needed to compensate for their negative R&D productivity through mergers and acquisitions.
研发生产力一直是行业的重大挑战。我们分析了 16 家领先的以研究为基础的制药公司在过去 20 年（2001-2020 年）的研发投入、产出和成果。我们的分析表明，制药公司的研发支出以 6%的复合年增长率增长（2001-2020 年），至每家公司平均研发支出 67 亿美元（2020 年）。我们调查的公司推出了 251 种新药，占过去 20 年所有与 CDER 相关的 FDA 批准的 46%。大型制药公司的平均研发效率为每款新药 61.6 亿美元的总研发支出。近一半的领先公司需要通过并购来弥补其负的研发生产力。
Zotero 插件